SR | Efficacy and safety of IL-6 inhibition with biological DMARDs in immune-mediated inflammatory diseases.

A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases – RMD Open

Commentary on Twitter

Check out our latest systematic literature review on IL-6 inhibition in immune-mediated inflammatory diseases:

▶️ positive clinical in a group of diseases
▶️ benefits in #COVID-19
▶️ similar safety outcomes vs other bDMARDs

? https://t.co/N1S9H2NrLQ pic.twitter.com/IAFGoEgkrY

— ARD & RMD Open (@ARD_BMJ) September 29, 2022